WST WEST PHARMACEUTICAL SVSC INC revenue, earnings and financials

For the quarter ended June 30, 2026, WEST PHARMACEUTICAL SVSC INC reported revenue of $872M (up 13.8% from a year earlier), net income of $154M and diluted EPS of $2.15; over the last four quarters revenue was $3.33B and net income $565M; for the fiscal year ended December 2025 revenue was $3.07B, up 6.3% on the year before.

WST annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.07B, gross profit $1.10B, operating income $585M, net income $494M (margin 16.1%), EPS $6.79
• Fiscal year ended Dec 2024: revenue $2.89B, gross profit $999M, operating income $570M, net income $493M (margin 17.0%), EPS $6.69
• Fiscal year ended Dec 2023: revenue $2.95B, gross profit $1.13B, operating income $676M, net income $593M (margin 20.1%), EPS $7.88
• Fiscal year ended Dec 2022: revenue $2.89B, gross profit $1.14B, operating income $734M, net income $586M (margin 20.3%), EPS $7.73
• Fiscal year ended Dec 2021: revenue $2.83B, gross profit $1.18B, operating income $752M, net income $662M (margin 23.4%), EPS $8.67

WST quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $872M (up 13.8% year over year), net income $154M, EPS $2.15
• Quarter ended Mar 31, 2026: revenue $845M (up 21.0% year over year), net income $139M, EPS $1.92
• Quarter ended Dec 31, 2025 (from the annual report): revenue $805M (up 7.5% year over year), net income $132M, EPS $1.82
• Quarter ended Sep 30, 2025: revenue $805M (up 7.7% year over year), net income $140M, EPS $1.92
• Quarter ended Jun 30, 2025: revenue $767M (up 9.2% year over year), net income $132M, EPS $1.82
• Quarter ended Mar 31, 2025: revenue $698M (up 0.4% year over year), net income $89.8M, EPS $1.23
• Quarter ended Dec 31, 2024 (from the annual report): revenue $749M (up 2.3% year over year), net income $130M, EPS $1.78
• Quarter ended Sep 30, 2024: revenue $747M (down 0.1% year over year), net income $136M, EPS $1.85
• Quarter ended Jun 30, 2024: revenue $702M (down 6.9% year over year), net income $111M, EPS $1.51
• Quarter ended Mar 31, 2024: revenue $695M (down 3.0% year over year), net income $115M, EPS $1.55
• Quarter ended Dec 31, 2023 (from the annual report): revenue $732M (up 3.3% year over year), net income $137M, EPS $1.83
• Quarter ended Sep 30, 2023: revenue $747M (up 8.8% year over year), net income $161M, EPS $2.14
• Quarter ended Jun 30, 2023: revenue $754M (down 2.3% year over year), net income $155M, EPS $2.06
• Quarter ended Mar 31, 2023: revenue $717M (down 0.5% year over year), net income $140M, EPS $1.85
• Quarter ended Dec 31, 2022 (from the annual report): revenue $709M (down 3.0% year over year), net income $103M, EPS $1.37
• Quarter ended Sep 30, 2022: revenue $687M (down 2.8% year over year), net income $121M, EPS $1.59
• Quarter ended Jun 30, 2022: revenue $771M (up 6.6% year over year), net income $189M, EPS $2.48
• Quarter ended Mar 31, 2022: revenue $720M (up 7.4% year over year), net income $174M, EPS $2.29
• Quarter ended Dec 31, 2021 (from the annual report): revenue $731M, net income $148M, EPS $1.90
• Quarter ended Sep 30, 2021: revenue $707M, net income $176M, EPS $2.31

WST cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $755M, share buybacks $134M, dividends $0.86 per share
• Fiscal year ended Dec 2024: operating cash flow $653M, share buybacks $561M, dividends $0.82 per share
• Fiscal year ended Dec 2023: operating cash flow $777M, share buybacks $438M, dividends $0.78 per share
• Fiscal year ended Dec 2022: operating cash flow $724M, share buybacks $203M, dividends $0.74 per share
• Fiscal year ended Dec 2021: operating cash flow $584M, share buybacks $137M, dividends $0.70 per share

WST balance sheet

• Jun 30, 2026: cash $436M, total assets $4.08B, total liabilities $1.09B, shareholders' equity $2.99B, long-term debt $203M
• Mar 31, 2026: cash $521M, total assets $4.11B, total liabilities $1.12B, shareholders' equity $2.99B, long-term debt $203M
• Dec 31, 2025: cash $791M, total assets $4.27B, total liabilities $1.09B, shareholders' equity $3.18B, long-term debt $203M
• Sep 30, 2025: cash $629M, total assets $4.11B, total liabilities $1.05B, shareholders' equity $3.05B, long-term debt $203M
• Jun 30, 2025: cash $510M, total assets $3.95B, total liabilities $1.02B, shareholders' equity $2.93B, long-term debt $203M
• Mar 31, 2025: cash $404M, total assets $3.62B, total liabilities $935M, shareholders' equity $2.68B, long-term debt $203M
• Dec 31, 2024: cash $485M, total assets $3.64B, total liabilities $961M, shareholders' equity $2.68B, long-term debt $203M
• Sep 30, 2024: cash $491M, total assets $3.68B, total liabilities $923M, shareholders' equity $2.75B, long-term debt $203M

What is WST's revenue?

WEST PHARMACEUTICAL SVSC INC reported $3.33B of revenue over its last four quarters, through June 30, 2026.

Is WST profitable?

Yes. WEST PHARMACEUTICAL SVSC INC earned $565M over the last four quarters.

What is WST's EPS?

Diluted earnings per share over the last four quarters were $7.81; $2.15 in the latest quarter.

Does WST pay a dividend?

WEST PHARMACEUTICAL SVSC INC paid $0.86 per share in dividends in the fiscal year ended December 2025.

WST ownership and insider trades · All stocks